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Abstract 
Treatment of advanced heart failure with implantable LVADs is increasing, driven by profound unmet patient 
need despite potential serious complications: bleeding, infection, and thrombus. The experimental objective 
was to develop a sensitive imaging approach to assess early thrombus accumulation in LVADs under 
operational high flow and high shear rates.  
Methods: A monomeric bifunctional ligand with a fibrin-specific peptide, a short spacer, and 99mTc chelating 
amino acid sequence (F1A) was developed and compared to its tetrameric PEG analogue (F4A).  
Results: 99mTc attenuation by LVAD titanium (1 mm) was 23%. 99mTc-F1A affinity to fibrin was Kd ~10 µM, 
whereas, the bound 99mTc-F4A probe was not displaced by F1A (120,000:1). Human plasma interfered with 
99mTc-F1A binding to fibrin clot (p<0.05) in vitro, whereas, 99mTc-F4A targeting was unaffected. The 
pharmacokinetic half-life of 99mTc-F4A was 28% faster (124±41 min) than 99mTc-F1A (176±26 min) with both 
being bioeliminated through the urinary system with negligible liver or spleen biodistribution. In mice with 
carotid thrombus, 99mTc-F4A binding to the injured carotid was much greater (16.3±3.3 %ID/g, p=0.01) than 
that measured with an irrelevant negative control, 99mTc-I4A (3.4±1.6 %ID/g). In an LVAD mock flow-loop (1:1, 
PBS:human plasma:heparin) operating at maximal flow rate, 99mTc-F4A bound well to phantom clots in 2 min 
(p<0.05), whereas 99mTc-F1A had negligible targeting. Excised LVADs from patients undergoing pump exchange 
or heart transplant were rewired, studied in the mock flow loop, and found to have spatially variable fibrin 
accumulations in the inlet and outlet cannulas and bearings.  
Conclusions: 99mTc-F4A is a high-avidity prototype probe for characterizing thrombus in LVADs that is 
anticipated to help optimize anticoagulation, reduce thromboembolic events, and minimize pump exchange. 
Key words: LVAD, thrombosis, nuclear imaging, fibrin, technetium 
Introduction 
Heart failure (HF) annually affects over five 
million Americans of all ages, both sexes, and all races 
[1]. Patients with refractory Stage D heart failure have 
limited options: 1) heart transplantation, but only 
3,000 donor hearts are available annually; 2) 
mechanical circulatory support, such as a left 
ventricular assist device (LVAD); or 3) hospice care 
with death typically transpiring within months [2-5]. 
While LVAD placement offers benefits to many 
patients with severe HF, their successful clinical use 
requires prevention and management of well-known 
complications: 1) gastrointestinal bleeding (GIB) due 
to platelet dysfunction secondary to the high shear 
effects [6], 2) bacterial infections along the 
percutaneous driveline, 3) intra-pump thrombus and 
stroke [7-9]. In terms of hospital readmissions, 
bleeding, infection, and thrombus were 30%, 22%, and 









Prevention of GI bleeding through refinement and 
shifting of the warfarin International Normalized 
Ratio (INR) guideline ranges and manipulation of the 
timing and extent of antiplatelet and anticoagulation 
regimen used has had anecdotal but no generalized 
clinical success [10-12]. Multicenter results indicated 
unexpectedly that lowering the INR range to reduce 
bleeding events tripled the incidence of pump 
thrombotic complications [12, 13]. Efforts to manage 
anticoagulation and minimize bleeding events are 
complicated by the lack of a sensitive, direct 
biomarker to characterize LVAD thrombus 
accumulation or rule it out. 
The sensitive and specific diagnosis of pump 
thrombus remains a clinical dilemma [14-18]. 
Currently, pump thrombus is suspected based on 
indirect evidence of increased erythrocyte hemolysis, 
such as elevated serum lactic dehydrogenase levels 
(LDH) and decreased serum haptoglobin, changes in 
LVAD power consumption, or by suggestive 
echocardiographic signs, such as new aortic valve 
opening or the lack of left ventricular (LV) 
decompression with dynamic testing [19]. 
Echocardiographic ramp studies offer early effective 
LV optimization of LVAD pump speeds and late 
pump thrombosis detection in patients suspected of 
clinical LVAD malfunction [20]. In rare cases, a large 
pump thrombus may be detected by computed 
tomography (CT) angiography [21]. 
Thrombus imaging has a rich history dating back 
to the mid 1970s and continuing to the present [22]. 
Both platelets and fibrin have been the dominant 
thrombus targets studied, but LVAD thrombus is 
typically an acellular fibrin accretion [23]. Acute 
vascular thrombi are readily imaged with virtually all 
clot-specific contrast agents, but aged thrombi greater 
than 48 h to 72 h are poorly targeted 
[22]. Thrombus homing is further 
degraded by anti-coagulation use, 
which may be clinically necessitated 
to prevent or treat suspected 
thrombosis [22]. LVAD thrombus 
develops over time despite 
concurrent anticoagulation with 
warfarin and aspirin [24, 25].  
Direct diagnosis and 
quantification of pump thrombus 
with noninvasive imaging is further 
complicated by the LVAD titanium 
housing, which precludes the use of 
magnetic resonance imaging (MRI), 
CT, or ultrasound and favors a 
nuclear medicine approach. Indeed, 
the high-shear and high blood flow 
conditions created by an LVAD, such 
as the HeartMate II (HMII, 
Abbott-Thoratec, Lake Bluff, 
Illinois), spinning at 8,800-10,000 
RPM, necessitate a probe with high 
molecular specificity and extreme 
binding avidity. Further, radioactive 
background in blood passing 
through the pump or accumulating 
in surrounding organs must be 
minimized to afford effective 
signal-to-noise. 
The objective of this project was 
to evaluate a sensitive and specific 
anti-fibrin probe prototype concept 
for targeting thrombus in the 
anticoagulated high-flow, high shear 
environment of LVADs. Monomeric 
and tetrameric 99mTc probes were 
 
Figure 1. A Diagrammatic representation of a HeartMate II (HMII) left ventricular assist device (LVAD). Blood 
(orange arrow) is drawn into the pump through a cannula from the ventricular apex, flows by the stator through 
the turbine and returns to systemic circulation through the outlet cannula into the aorta. The pump is powered 
through an externalized driveline cable on the outlet side of the LVAD. B Small residual LVAD thrombus on the 
inlet stator and around the bearing (C) from a patient admitted with elevated lactate dehydrogenase (LDH) 
(1300's) after symptomatic hemorrhagic/embolic stroke due to a suspected pump thrombus. White arrows point 
to residual thrombus. HMII image is copyright protected by Thoratec, Inc and used with permission. 
 





evaluated and compared in vitro for fibrin clot 
binding signal in PBS, with and without a strong 
amino acid tridentate ligand (cysteine), and plasma. 
Pharmacokinetic and biodistribution studies of the 
monomeric and tetrameric nuclear probes were 
delineated along with selective in vivo targeting to 
carotid thrombus in mice. The relative binding of the 
monomeric and tetrameric probes to acute fibrin clots 
were compared within a Heartmate II mock loop 
flowing heparinized plasma:PBS at approximately 6 
L/min. 99mTc attenuation through titanium, as used in 
the pump housing, was characterized. LVADs excised 
from patients undergoing heart transplant or LVAD 
exchange were rewired and exposed to the tetrameric 
fibrin probe in the mock flow-loop system under near 
maximal flow conditions followed by high-resolution 
NanoSPECT imaging assessments to assess inherent 
accumulation of intra-pump thrombus. The 
overarching result of this proof-of-concept study 
suggests that direct imaging assessments of LVAD 
thrombus accumulation, or lack thereof, could 
improve and individualize patient management 
decisions with the potential to minimize thrombotic 
events, decrease hemorrhaging, and reduce surgical 
pump exchanges.  
Materials and Methods 
Solid phase synthesis of monomeric (F1A) and 
tetrameric (F4A) fibrin probes  
 Monomeric unit (F1A) is a bifunctional entity 
comprising a fibrin-specific natural peptide analogue 
(QIWCLGYPCEWQ) [26] interconnected through a 
diethylene glycol (DEG) spacer to a 
technetium-chelating amino acid sequence 
(HHE-DEG) (Figure 2A). PEG2000 tetramer was used to 
couple four F1A monomers to form F4A (Figure 2B). 
Briefly, peptide precursors were synthesized with a 
CS136 peptide synthesizer at a 0.2 mmol scale. 
Standard solid phase Fmoc peptide synthesis was 
used [27]. F1A was synthesized with high purity 
(>95%). The final product was analyzed by HPLC and 
ESI-TOF mass spectrometry: ESI-TOF (positive 
mode): m/z [C94H126N24O26S2 + 2H]+ Calcd. 
1036.4 Da.; Obsd. 1036.3 Da. To obtain the 
tetramer, the side-chain protecting group, 
4-{N-[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-me
thylbutyl]-amino}benzyl (Dmab) was selectively 
removed from glutamate and coupled with the 
4-arm-PEG amine (PSB-431, 2K, Creative PEGWorks, 
Chapel Hill, NC). F4A was purified with size 
exclusion chromatography (Zeba Desalt Spin 
Column, 2 mL, ThermoScientific) using 10% acetic 
acid in water followed by three deionized water 
washes. The overall yield of F4A was <10%. MALDI 
characterization of the product revealed an array of 
molecular weights arising from an unexpectedly high 
polydispersity of the tetrameric PEG core. (See 
Supplementary Material). 
99mTc labeling of F1A and F4A 
F1A and F4A were radiolabeled to the HHE 
sequence with 99mTc for gamma imaging [28]. This 
was accomplished by adding Na99mTcO4 (~9 mCi; 1.0 
mL) in saline to an IsoLink vial (Center for 
Radiopharmaceutical Sciences of PSI, ETH and USZ, 
Paul Scherrer Institute, Switzerland). 99mTc-F1A 
optimally binds one 99mTc nuclide and the 99mTc-F4A 
chelates up to four metal atoms, one on each arm 
(Figure 2B). Given the rapid radioactive decay of 99mTc 
to 99Tc as well as the elution status of the 
molybdenum generator yield, typical specific 
activities of the 99mTc-F1A and 99mTc-F4A probes were 
40 mCi/µmol with 90% to 95% radiochemical purity 
based on radio-thin layer chromatography (0.1 M 
NaAc pH 5.18:MeOH:H2O = 20:100:200). 
 Acellular fibrin clot assays  
Acellular fibrin clots were used: 1) to 
characterize the binding affinity of 99mTc-F1A and the 
relative avidity of 99mTc-F4A, 2) to assess the stability 
of 99mTc chelation, and 3) to evaluate the matrix effect 
of plasma on the probe binding to fibrin clots. 
Uniform clots were produced by quickly admixing 
100 µL of fresh frozen human plasma with 3 U 
thrombin and calcium chloride (Sigma-Aldrich 
Chemical, St. Louis, MO). The mixture was pipetted 
into uniform cylindrical plastic tubes. Once formed, 
clots were washed repeatedly in 0.1 M PBS buffer (pH 
7.0) then stored at 4 °C in same until use.  
Fibrin binding affinity 
 99mTc-F1A (20 µCi) was incubated with the clot 
samples at 37 °C for 30 min with 1, 5, 10, 15, 25, and 30 
µg cold monomer supplemented with 0.1 M PBS pH 
7.4 to bring each test volume total to 0.5 mL. The fibrin 
clots were separated from unbound radioactivity by 
repeated centrifugation and washing then were 
counted in a calibrated well counter (Wizard 3, Perkin 
Elmer, Waltham, MA). Results, adjusted for decay, 
were used to estimate the dissociation constant (Kd) 
using the Hill slope model (h), 
Y=Bmax*Xh/(Kdh + Xh) (MatLab, Natick, MA) where 
Kd is the ligand concentration that binds to half the 
receptor sites at equilibrium, Bmax is the maximum 
number of binding sites, X is the radioligand 
concentration and h is the Hill slope, an estimate of 
binding cooperativity. Total fibrin concentration was 
estimated from plasma fibrinogen to be 0.735 nmol 
per clot. 99mTc-F4A (20 µCi) was incubated with the 





clot samples at 37 °C in the presence of unlabeled F1A, 
which was titrated to a 120,000:1 excess relative to 




Assessment of 99mTc-F1A and 99mTc-F4A 
radiolabel stability and plasma interference 
 Radiolabeled F1A and F4A were bound to clots 
in the presence of marked excess cysteine to evaluate 
the stability of the 99mTc label in triplicate [29]. 
99mTc-F1A or 99mTc-F4A (20 µCi) supplemented with 
0.1 M PBS pH 7.4 (total volume of 0.5 mL) were 
incubated with fibrin clot samples at 37 °C for 30 min. 
 
Figure 2. A 99mTc carbonyl aqua-ion and the complex formed with HH-peptide. B 99mTc-F1A bi-functional monomer depicting the cyclic homing sequence, short spacer, and 
99mTc-chelating site depicting 99mTc carbonyl coupling. C 99mTc-F4A tetramer created by the balanced cross-linking of the four F1A monomers with tetrameric PEG arms (shown 
with one example of 99mTc on one of the four arms for clarity). PEG: polyethylene glycol. Bold arrows point to 99mTc carbonyl coupling in example illustrations.  





Similarly, the 0.1 M PBS buffer diluted 50% with fresh 
frozen human plasma (total volume of 0.5 mL) was 
used to assess potential plasma matrix interference on 
radiolabeled peptide binding in triplicate. In both 
instances, fibrin clots were separated from unbound 
radioactivity by repeated centrifugation, were 
washed, then counted in a calibrated well counter 
(Wizard 3, Perkin-Elmer).  
Gamma signal attenuation from titanium 
LVAD housing 
Na99mTcO4 was serially diluted into plastic 
snap-cap vials from 20 µCi to 0.5 µCi and radioactivity 
was evaluated using the Multispectral FX multimodal 
imaging system (Bruker-Biospin, Billerica, MA) with 
the isotope phosphor screen for planar scintigraphy 
using a 1.0 min acquisition time. Samples were 
imaged before and after placement of a 1 mm titanium 
sheet provided by Thoratec Corp., which 
corresponded to the titanium metal used to form the 
LVAD HMII housing.   
Pharmacokinetics (PK) and biodistribution 
(BD) of 99mTc-F1A and 99mTc-F4A in mice 
All animal research was conducted under a 
protocol approved by the Washington University 
Animal Studies Committee. 
 The pharmacokinetics of 99mTc-F1A and 
99mTc-F4A were studied in triplicate in mice (male, 
Harlan, C57BL/6, 4-6 wks). Mice were anesthetized 
with ketamine (85 mg/kg) / xylazine (10 mg/kg) and 
maintained with 1-2% isoflurane through a nosecone. 
99mTc-F1A or 99mTc-F4A (16-30 µCi) were injected via 
tail vein and serial blood samples were obtained at 0, 
2, 5, 10, 15, 20, 30, 60, 120, and 180 min via an 
indwelling jugular catheter. Blood samples were 
timed, weighed, and counted with a calibrated 
gamma counter (Wizard 3, Perkin-Elmer). The data 
were adjusted for decay relative to the time of 
counting and were fit to bi-exponential models using 
MatLab (Natick, MA). After 180 min animals were 
euthanized; tissue and fluid aliquots (bladder, brain, 
GI, heart, lung, liver, spleen, urine, body remains) 
were excised, weighed, counted, and the results 
adjusted for decay relative to the time of counting. 
Biodistribution and pharmacokinetic results were 
expressed as percent of actual injected dose per gram 
tissue or fluid (%ID/g). 
Efficacy of 99mTc-F4A in mice with carotid 
thrombus 
 In vivo targeting of 99mTc-F4A was performed in 
mice (male, Harlan, C57BL/6, 4-6 wks) following the 
introduction of a carotid thrombus using the Rose 
Bengal method. [30, 31] Briefly, mice were 
administered 60 µg/g body weight by tail vein 
injection of a 20 mg/mL solution of Rose Bengal dye 
(the singlet oxygen was generated by the 
photoactivation of the dye). HeNe laser (540 nm, 1.5 
mW/cm2) was focused for 45 min to 50 min on a 
surgically exposed carotid artery distal to a Doppler 
cuff probe until blood flow was decreased at least 70% 
relative to baseline. After laser treatment, the mice 
were heparinized and 99mTc-F4A (n=4) or an irrelevant 
peptide (GGSHPSRPRAG) tetrameric 99mTc-control 
(99mTc-I4A, n=4, 3 µCi/g BW, ~75 µCi/mouse). At 2 h, 
%ID/g of the thrombotic carotid and its contralateral 
control vessel were determined using an automatic 
well counter (Wizard 3, Perkin-Elmer). To confirm in 
vivo imaging efficacy, an additional secondary cohort 
of 5 mice with carotid thrombus created as above 
were administered 40 mCi of 99mTc-F4A and imaged 
two hours later with a Multispectral FX multimodal 
imaging system (Bruker-Biospin, Billerica, MA) with 
the isotope phosphor screen for planar scintigraphy 
using a 1.0 min acquisition time. 
Fibrin targeting in an LVAD mock flow loop  
A HMII LVAD controlled by a computer console 
was inserted into a 200 mL mock flow loop comprised 
of ½” plastic tubing interconnecting a PBS:fresh 
heparinized human plasma (1:1) reservoir, an 
injection port, a media drainage port, and an inline ½” 
plastic chamber. Uniform human fibrin clots aged 24 
h were supported within the inline chamber using a 
highly porous, single thread layer of cotton gauze. 
The LVAD was operated at maximum flow rate 
(~10,000 RPM, 6 L/flow per minute). 99mTc-F4A or 
99mTc-F1A (0.5 mCi) were injected into the loop and 
allowed to circulate for 2 min followed by a 2 min 
plasma/PBS wash to remove unbound radioactivity. 
Recovered clot radioactivity was counted in a 
calibrated gamma well counter and the results 
adjusted for decay. 
Targeting of thrombus in excised LVADs using 
a mock flow loop  
 HMII excised (n=5) from patients without 
clinical suspicion of pump thrombus were rewired for 
operation in the heparinized human plasma:PBS (1:1) 
mock loop and operated at the preprogrammed 
patient controller pump rate of (9400 RPM). 99mTc-F4A 
(0.5 mCi) was injected into the loop for 30 min then 
washed with fresh circulating plasma/PBS for 2 min. 
The pumps were removed from the loop and imaged 
with single-photon emission computed tomography 
(SPECT) with CT (NanoSPECT/CT, Bioscan, Inc., 
Poway, CA). Helical SPECT and CT scans were 
performed with 8 projections per rotation for 5 min 
per projection and 65 kVp, 177 µAs, respectively, and 





reconstructed with Invivoscope software. Total 
photon counts were calibrated to total radioactivity of 
the sample.  
Statistical Analysis 
Data were analyzed using Student's T-Tests, 
paired T-tests, or analysis of variance (SAS Inc., Cary, 
NC). Data are presented as the mean ± standard error 
of the mean unless otherwise stated. In vivo targeting 
of carotid thrombus was a completely randomized 
design replicated to allow detection of a 20% 
difference with 80% power at an alpha level of 0.05.  
Results 
99mTc-F1A and 99mTc-F4A fibrin affinity, 
radiolabel stability, plasma interference  
The binding affinity, radio-stability, and plasma 
matrix effects of the 99mTc-F1A and 99mTc-F4A probes 
were characterized. Titrated dosages of 99mTc-F1A 
bound to uniform fibrin clots in PBS with good 
affinity (Kd ~10.2 µM), which was consistent with the 
earlier report and phage display-derived peptides in 
general [26] (Figure 3A). By comparison, 99mTc-F4A 
bound with extraordinary affinity and avidity to 
analogous fibrin targets in PBS. 99mTc-F4A bound to 
each clot was not displaced by unlabeled F1A titrated 
to 120,000 molar excess relative to 99mTc-F4A, 
reflecting extraordinary avidity (Figure 3B). 
 Radiolabel stability of 99mTc-F1A and 99mTc-F4A 
probes was studied in the presence of excess cysteine, 
a strong tridentate ligand. Fibrin clot nuclear signal 
measured for 99mTc-F1A or 99mTc-F4A binding in PBS 
with or without cysteine did not differ (p>0.05) 
(Figure 3C, D). However, the binding of 99mTc-F1A to 
fibrin clots in the presence of human plasma was 
severely compromised (p<0.05) compared with PBS 
 
Figure 3. A Titrated dosages of 99mTc-F1A bound to uniform fibrin clot in PBS. The dissociation constant (Kd ~10.2 µM) was adjusted for decay and estimated using the Hill 
slope model, Y=Bmax*Xh / (Kdh + Xh) three times independently (± s.e.m.). Total fibrin concentration was estimated from plasma fibrinogen (0.735 nmol per clot). B The 
percentage of 99mTc-F4A bound to each clot in the presence of unlabeled F1A (monomer) at molar ratios up to 120,000 to 1. 99mTc-F1A (C) and 99mTc-F4A (D) bound to clots 
in the presence of PBS and in PBS with excess cysteine to demonstrate 99mTc labelling stability. However, in a 50:50 PBS:human plasma mixture the binding of 99mTc-F1A to clot 
was dramatically reduced (p<0.05) whereas 99mTc-F4A was unaffected. E The attenuation of Na99mTcO4 from 20 µCi down to 0.5 µCi by titanium plate (1 mm), equivalent to the 
housing of HMII, was 23% ± 3% independent of radioactivity level (n=3/level). HMII: HeartMate II; PBS: phosphate buffered saline. 





alone, indicating a significant matrix effect (Figure 
3C). In contradistinction, 99mTc-F4A binding was 
unaffected by human plasma: the probe bound 
equivalently to the fibrin clots in PBS and in plasma 
(p>0.05) (Figure 3D). Of note, a slight increase in 
99mTc-F4A fibrin signal was appreciated in the 
presence of plasma, which may reflect blockage of 
nonspecific binding sites on the plastic well walls, 
increasing the bioavailability of the free 99mTc-F4A 
probe to interact with the clots.  
Nuclear signal attenuation due to titanium 
LVAD housing 
The decision to approach the LVAD thrombus 
diagnosis problem with a nuclear medicine solution 
reflected the need for the probe signal to penetrate 
through the titanium pump housing. The attenuation 
of Na99mTcO4 by a titanium plate of equivalent quality 
and thickness (1 mm) to that used to form the housing 
for HMII was evaluated by titrating the isotope 
concentration from 20 µCi down to 0.5 µCi. Gamma 
scintigraphy imaging of the phantoms with and 
without the titanium sheet shielding revealed 23% ± 
3% nuclear signal attenuation independent of the 
level of radioactivity studied (Figure 3E). The 
influence of signal attenuation due to the titanium 
housing, although present, was relatively minor, 
permitting both the high sensitivity and quantitative 
gamma imaging. 
Pharmacokinetics (PK) and biodistribution 
(BD) of 99mTc-F1A and 99mTc-F4A in mice 
The pharmacokinetics (PK) and biodistribution 
(BD) of the reference radiolabeled 99mTc-F1A were 
compared to that of the 99mTc-F4A in mice in triplicate. 
Both agents closely followed a two-compartment 
bi-exponential PK model (Figure 4A, B). The alpha 
distribution half-life of 99mTc-F4A in mice (5.0 ± 1.9 
min) was 41% faster (p<0.05) than that of 99mTc-F1A 
(8.6 ± 1.9 min). Similarly, the beta elimination half-life 
of 99mTc-F4A (124.7 ± 41.3 min) was 50 min shorter 
(28%) than 99mTc-F1A (174.2 ± 26.2 min) (p= 0.08), 
which was likely related to the minimal plasma 
interactions with 99mTc-F4A.  
The organ biodistribution of both agents at the 
conclusion of the PK study (180 min) was very similar 
with neither probe accumulating substantially in the 
lung, liver or spleen. Such low uptake by 
reticuloendothelial organs reflects the relatively small 
sizes of 99mTc-F1A and 99mTc-F4A. Essentially, all of 
the 99mTc activity was excreted through the urinary 
system into kidney, bladder or urine at the 3 h 
sampling time point (Figure 4C, D). These data 
suggest that background circulating 99mTc-F4A blood 
pool levels will decrease rapidly without significant 
tissue accumulation, minimizing the time between 
probe injection and signal readout.  
Efficacy of 99mTc-F4A in mice 
The targeted binding of 
99mTc-F4A to carotid thrombus was 
robust and occurred in every animal 
studied: carotid clot, 16.3 ± 3.3 
%ID/g versus contralateral carotid 
(no clot), 3.1 ± 1.5 %ID/g, p<0.05 
(Figure 5). 99mTc-I4A had poor 
carotid clot binding: carotid clot, 3.4 
± 1.6 %ID/g versus the contralateral 
clot-free carotid, 1.1 ± 0.5 %ID/g, 
p<0.05. As expected, 99mTc-F4A (16.3 
± 3.3 %ID/g) binding to the injured 
carotid was much greater (p<0.05) 
than that measured with 99mTc-I4A 
(3.4 ± 1.6 % ID/g). These data 
corroborate that 99mTc-F4A 
effectively, specifically, and 
systemically targeted native carotid 
thrombus in vivo.  
In a separate cohort of mice 
bearing carotid thrombus, 99mTc-F4A 
was administered by tail vein 
injection and mice were imaged 
using Multispectral FX multimodal 
 
Figure 4. The pharmacokinetics (PK) and biodistribution (BD) of the reference radiolabeled 99mTc-F1A compared 
to 99mTc-F4A in mice (n=3/treatment). A Both agents, presented as percent injected radioactivity per gram blood 
(%ID/g), closely followed a two-compartment bi-exponential PK model. B The alpha distribution half-life of 
99mTc-F4A in mice (5.0 ± 1.9 min) was 41% faster (p=0.04) than that of 99mTc-F1A (8.6 ± 1.9 min). Similarly, the beta 
elimination half-life of 99mTc-F4A (124.7 ± 41.3 min) was 50 min shorter (28%) than that of 99mTc-F1A (174.2 ± 26.2 
min) (p= 0.08), which were likely related to minimal plasma interactions with 99mTc-F4A. Mouse organ 
biodistribution including body remains (n=3/treatment) of 99mTc-F1A (C) and 99mTc-F4A (D) at the conclusion of 
the PK study (180 min) were similar. Neither probe accumulated substantially in the lung, liver or spleen. Virtually 
all of the 99mTc activity was excreted through the urinary system (kidney, bladder and urine).  





imaging system (Bruker-Biospin, Billerica, MA) after 2 
h. Figure 5B provides a representative in vivo image 
showing robust signal (arbitrary units) in the targeted 
carotid with negligible contrast in the uninjured 
contralateral vessel. These data suggest that the 
binding to carotid thrombus occurs relatively soon 
after injection of 99mTc-F4A, resulting in strong 
contrast greater than the circulating background and 
the contralateral artery at 2 h. 
Ex vivo LVAD flow study using a mock loop 
The high shear and high blood flow (~6 L/min) 
of the LVAD required to pump the entire circulating 
blood volume of the patient every minute place severe 
demands on probe binding affinity and clot retention 
of the nuclear probe. Therefore, fibrin clot 
accumulation of the reference probe, 99mTc-F1A, and 
99mTc-F4A were compared in triplicate under the 
maximal flow and shear conditions produced by a 
HMII using a mock loop circulating a 
plasma:PBS:heparin mixture (Figure 6B). After 2 min 
of circulation, 99mTc-F4A was rapidly bound and 
retained on the clot whereas the monomeric reference, 
99mTc-F1A, was associated at only negligible levels 
(p<0.01) (Figure 6A). The superior binding of 
99mTc-F4A to fibrin clots under high flow conditions 
illustrated the advantage of the high avidity 
PEG-based tetrameric design for increasing fibrin 






Figure 5. Targeted fibrin binding of 99mTc-F4A to carotid thrombus was compared to an irrelevantly targeted 99mTc-I4A probe (~75 µCi/animal). A The signal from the 
clot-bearing carotid (%ID/g) was compared to the clot-free contralateral vessel response. 99mTc-F4A binding to carotid thrombus was much greater than uptake in the clot-free 
contralateral carotid vessel (p<0.05). 99mTc-I4A bound poorly to carotid thrombus and nuclear probe uptake did not differ from the nonspecific signal obtained in the clot-free 
carotid. Binding of the fibrin-specific 99mTc-F4A to carotid clot was markedly greater (p=0.01) than the nonspecific binding of 99mTc-I4A to thrombus. *p<0.05. B Representative 
maximum intensity projection image with a color map (arbitrary units) from 1 of 5 mice administered 99mTc-F4A (40 µCi) by tail vein injection then imaged 2 h later with a 
Multispectral FX multimodal imaging system (Bruker-Biospin, Billerica, MA). A Marked single source signal originating from the right carotid thrombus was noted. All animals 




Figure 6. A HMII mock flow loop design: circulation media was 200 mL of heparinized 50:50 plasma:PBS. Activity injected for each probe was 0.5 mCi. B Average percent 
radioactivity (± s.e.m.) of 99mTc-F4A versus 99mTc-F1A bound to uniform fibrin clots after 2 min of circulation in HMII mock flow loop. *p<0.05, n=3/treatment group, HMII: 
HeartMate II 






Figure 7. 99mTc-F4A signal was assessed for the inlet cannula (metallic and Dacron® segments), the inlet stator/bearing, turbine, outlet bearing, and outlet cannula regions. Strong 
99mTc-F4A signals were noted in the metallic and Dacron® inlet cannula segments in A and in the flexible, Dacron® segment in panel B. Prominent 99mTc-F4A signal was observed 
around the inlet bearing in C and both the inlet and outlet bearings/stator in D. Fibrin accumulation coating the walls of the outlet cannulas were frequently noted as in E. This 
LVAD was notable also for thrombus associated with the inlet and outlet bearings. Yellow arrows in each image point to regions of 99mTc-F4A signal corresponding to fibrin 
deposition and accumulation. Abbreviated clinical histories: A Implanted 520 days. Early hemolysis after implantation. Peak LDH 1300 U/L. Resolved with eptifibatide and 
bivalrudin. B Implanted 830 days. No hemolysis. Routine transplant. C Implanted 146 days. Hemolysis noted with a peak LDH 800 U/L. Negative ramp study. LDH trended 
downward and the heart was transplanted soon thereafter. D Implanted 410 days. Sustained hemolysis with a LDH peak 3400 U/L. Pump exchanged for suspected pump 
thrombosis. E Ischemic stroke 7 days after implantation. No hemolysis. Pump exchanged. LVAD: left ventricular assist device; LDH: lactic dehydrogenase. 
 
Assessments of thrombus in explanted rewired 
LVADs in a mock loop with 99mTc-F4A 
For further proof of concept of this clot-binding 
contrast agent, 99mTc-F4A binding was assessed in 
explanted LVADs from patients (examples of 5 from 
over 60 pumps evaluated are shown) receiving heart 
transplants or surgical pump exchange to 
demonstrate the imaging agent affinity for the native 
intra-pump fibrin deposition and to determine if high 
resolution imaging could spatially characterize the 
extent of thrombus formation (Figure 7). 99mTc-F4A 
signal was assessed for the inlet cannula (metallic and 
Dacron® graft segments), the inlet stator/bearing, 
turbine, outlet bearing, and outlet cannula regions. 
Strong 99mTc-F4A signals were noted in the metallic 
and Dacron® inlet cannula segments in Figure 7A and 
in the flexible, Dacron® segment in Figure 7B. 
Prominent 99mTc-F4A signal around the inlet bearing 
in Figure 7C and both the inlet and outlet 
bearings/stator in Figure 7D were also observed. 
Fibrin accumulation coating the walls of the outlet 
cannulas was frequently noted as in Figure 7E. The 
occasional LVAD had no detectable 99mTc-F4A, but 
the prevalence of HMII pumps with detectable fibrin 
using a nanoSPECT/CT imaging was high in an 
initial cohort (17/18). Inherent nonspecific binding of 
99mTc-F4A to the LVAD pump was nondetectable 
(Figure S1). Additionally, six pumps were submitted 
to the vendor for independent pathologic evaluation 
and corroborated the nuclear imaging results 
(Figure S2). 
Discussion  
Detection and characterization of LVAD 
thrombus is an unmet medical need with significant 
clinical importance in the heart failure community not 
only for diagnosing pump thrombosis but for better 
individualizing anticoagulation regimens. 99mTc-F4A 
is a prototype tetrameric nuclear probe capable of 
binding fibrin deposits in the high-shear high-flow 
chambers within LVADs and is detectable through 
the titanium pump housings. Four bifunctional 
monomeric probes (99mTc-F1A) were connected 
through a tetrameric polyethylene glycol core to form 
99mTc-F4A. In addition to overcoming high shear, this 
prototype probe effectively targeted aged thrombus 
exposed long-term to anticoagulation, which virtually 
all fibrin-specific contrast agents have failed to target 
to date [22]. 
 As shown, 99mTc-F4A had extraordinary binding 
avidity to fibrin clots that could not be displaced in 
vitro by the F1A monomeric probe at ratios up to 
120,000:1 molar excess. Moreover, in the LVAD ex 
vivo mock flow loop, the binding affinity of 99mTc-F1A 
to fibrin clots was less than 99mTc-F4A. The 
bifunctional monomeric 99mTc-F1A and the tetrameric 
99mTc-F4A share the same cyclic peptide ligand and 
99mTc chelating strategy. While the monomeric probe 
can associate with a single fibrin fibril, the tetrameric 
PEG arms allow the 99mTc-F4A probe to interact with 
multiple fibrin fibrils or to bind around a single fibril 
at multiple sites. Hypotheses based on possible 3 
dimensional conformations will be complex to resolve 
but fascinating avenues for future study. 





 Hydrophobic peptide binding to plasma protein 
constituents is common among peptide-based probes 
in general, and was observed for 99mTc-F1A in the 
present study as plasma interference with binding in 
vitro. While the reported specific binding to plasma 
proteins such as albumin may be low on a micromolar 
basis, the concentrations of albumin and other plasma 
proteins in blood are very high (up to 3-4 g/dL). This 
large capacity of plasma proteins for nonspecific 
adsorption requires increased probe dosages for 
targeting purposes and can result in elevated 
persistent background signal, reducing detection 
sensitivity for critical small thrombin deposits 
associated with HMII pump bearings.  
  Indeed, almost all thrombus probes reported to 
date bind or accumulate in acute clots, typically less 
than 72 h, with poorer binding achieved as the 
thrombus ages and accessible fibrin content decreases. 
As an example, a recent promising fibrin-binding 
peptide (FBP8)-PET probe was reported to have 
efficacy towards acute thrombus, which then 
diminished quickly as the clot aged. This loss of fibrin 
binding paralleled a reduction in fibrin content as the 
clot organized [32, 33]. LVADs presented in this study 
were obtained from patients 7 to 830 days following 
implantation. In all instances, the thrombus was an 
acellular almost pure fibrin accretion. In published 
reports of severe cases, the intra-pump thrombus 
deposits had a "woody" layered appearance 
resembling growth rings in a tree trunk [34]. 
 Anticoagulation with warfarin and aspirin is 
prescribed chronically to diminish the incidence of 
thrombosis in LVADs. However, with exception of 
99mTc-NC100668, which employed a partial peptide 
analogue of alpha2-antiplasmin [35-37], 
thrombus-specific contrast agents have routinely 
failed to be effective in the presence of anticoagulation 
[22]. In the present study, 99mTc-F4A was effective 
against aged fibrin deposits in LVADs exposed to 
anticoagulation during patient use and during ex vivo 
evaluation in the mock-flow loops. 
Given the continued high bleeding and stroke 
rates associated with LVADs despite close 
management under current guidelines for 
anticoagulation management, 99mTc-F4A may offer a 
key tool to individualize anticoagulation goals for 
patients, improving management decisions that 
minimize GIB and strokes. Although fibrin deposits 
were noted in the outlet and inlet cannulas and 
bearings and occasionally along the axial rotor, the 
clinical relevance of thrombus accumulation in one 
pump region versus another remains to be fully 
resolved. LDH is often used as a surrogate clinical 
marker of pump thrombosis, particularly for very late 
conditions, but the early correlation between transient 
spikes in LDH and significant pump thrombosis is 
uncertain. Similarly, the correlation between LVAD 
operational voltage variations and spikes alone have 
not been reliable enough to warrant major clinical 
decisions, such as pump exchanges, and the 
relationship between voltage variation and transient 
pump thrombosis events remains unclear. 99mTc-F4A 
is anticipated to provide a robust metric to assess 
accumulation in LVAD thrombus to help individually 
tune anticoagulation (INR) targets to minimize stroke 
and bleeding risk. Periodic testing, particularly in 
response to clinical status triggers, could be used to 
affirm or adjust the clinical management plan over 
time.  
99mTc-F4A was developed with a previously 
characterized fibrin peptide analogue to test the 
concept of a tetrameric PEG cross-linked bifunctional 
probe as a means to overcome the LVAD challenges of 
aged clot, chronic anticoagulation, and high shear 
blood flow. While the potential success of this probe is 
supported by the data presented, chemistry 
improvements as well as further characterization are 
required. From a chemistry perspective, 99mTc-F4A 
utilized a commercially available tetrameric PEG core 
with unexpectedly high variability with regard to 
PEG arm lengths. This variability complicated 
analytically-supported process scale-up efforts 
required to conduct additional analytical, in vitro, and 
in vivo characterization studies. The next generation 
of probe(s) will require scalable synthesis of the 
tetrameric PEG including highly controlled individual 
PEG arm lengths. Additionally, while the present 
prototype probe was synthesized using solid phase 
chemistry, the scaled version of 99mTc-F4A will likely 
require the adoption of a solution phase method. 
Improvements in process and characterization will 
better support large animal LVAD homing studies 
and improved pharmacokinetic assessments, with 
high clinical translation relevance. 
In summary, 99mTc-F4A is a prototype probe 
incorporating a tetrameric PEG core found to achieve 
high avidity against aged fibrin with minimal plasma 
matrix interference for direct noninvasive LVAD 
thrombus assessments. 99mTc-F4A targeted fibrin 
effectively in vivo in mice as well as ex vivo in human 
excised LVADs rewired and operated in a mock-loop. 
Biodistribution studies demonstrated that the 
unbound probe cleared rapidly through the urinary 
system with negligible liver, spleen, or lung 
accumulation. 99mTc-F4A detected and spatially 
characterized thrombus in operational LVADs excised 
from patients with and without prior suspicion of 
pump thrombus. 99mTc-F4A could be applied to 
investigate biomarkers or clinical symptoms 
suggestive of pump thrombus formation as well as 





better individualize anticoagulation management to 
minimize bleeding while reducing thrombotic 
complications and pump exchanges. 
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